Actinium Pharmaceuticals, Inc. (ATNM) research
Actinium Pharmaceuticals, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.17
- As of
Actinium Pharmaceuticals, Inc. (ATNM): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-14.
As of . Source: SEC EDGAR filings for ATNM. Method and limitations.
Share the ATNM intelligence card
See ATNM live in the terminal
Track ATNM's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live ATNM terminal, freeActive signals for ATNM
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 502.7%, EPS $0.89 vs $-0.221 estimate
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +61% to ATNM (2026Q1)
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 38.4% - EPS $-0.22 vs $-0.357 estimate
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 5.0% - EPS $-0.2 vs $-0.1904 estimate
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 51.5% - EPS $-0.16 vs $-0.3298 estimate
FREE, NO ACCOUNT
Every signal on ATNM, as it fires
You are seeing 5 of 7 signals recorded on ATNM since 2026-05-31.
The five above landed across 4 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ATNM (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 00507W206 · 2026Q2 | $504K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 00507W206 · 2026Q2 | $373K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 00507W206 · 2026Q2 | $254K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ATNM
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
ATNM against its peers
ATNM's operating margin of -40274.4% ranks in the 15th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-03-31.
| Metric | ATNM | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 90000 USD | 789000 USD | 29 | 11 |
| Operating margin | -40274.4% | -706.2% | 15 | 9 |
| Net margin | -37652.2% | -471.6% | 14 | 10 |
| Return on equity | -432.6% | -102.4% | 8 | 17 |
Peers (21): MGX, ANVS, MREO, KPTI, ATYR, VERU, GRCE, CELU, HOWL, TVGN, IMMP, EDSA, IBO, CRVO, TIL, ELTX, MCRB, HRTX, FLNA, ELOX, GNTA. Left out: BETRF (period gap), LITS (no annual filing), SEOVF (no annual filing), HYFT (period gap). Fiscal periods ending between 2025-06-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (ATNM: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ATNM signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ATNMand get the insider, 13F, options, and confluence read in one view.